Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)116
G. Zhu
{"title":"Target Oncogenic Receptors in Tumours, A Hot Topics Today","authors":"G. Zhu","doi":"10.47363/jonrr/2021(2)116","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)116","url":null,"abstract":"","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121501313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)119
R. Bayramov
{"title":"Criteria for the Optimal Extent of Lymph Node Dissection for Gastric Carcinoma: Number of Harvested Lymph Nodes or Properly Dissected Relevant Lymph Node Stations? Standard or Personalized Extent?","authors":"R. Bayramov","doi":"10.47363/jonrr/2021(2)119","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)119","url":null,"abstract":"","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126116046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)120
Roxana Risco Neyra, P. F. Rivera
Central neurocytoma is considered a neoplasm classified as grade II by the WHO, of intraventricular location, although they can be aggressive. Due to the rare incidence, there are no fixed treatment rules or radiation therapy recommendations. Macroscopic total resection is usually curative, however, it is only achieved in 30-50% of cases due to the central location. Adjuvant treatment for optimal neurocytoma management should be considered. Stereotactic radiosurgery is now increasingly recommended as an adjuvant treatment. A case report of a patient treated with postoperative radiosurgery with high local control is presented, and the literature review is also performed.
{"title":"Radiosurgery with Gamma Knife in Central Neurocitoma: Case Report","authors":"Roxana Risco Neyra, P. F. Rivera","doi":"10.47363/jonrr/2021(2)120","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)120","url":null,"abstract":"Central neurocytoma is considered a neoplasm classified as grade II by the WHO, of intraventricular location, although they can be aggressive. Due to the rare incidence, there are no fixed treatment rules or radiation therapy recommendations. Macroscopic total resection is usually curative, however, it is only achieved in 30-50% of cases due to the central location. Adjuvant treatment for optimal neurocytoma management should be considered. Stereotactic radiosurgery is now increasingly recommended as an adjuvant treatment. A case report of a patient treated with postoperative radiosurgery with high local control is presented, and the literature review is also performed.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134230010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)124
A. Kuchkuntla, N. Nandu
Plasmacytomas are localized tumors of monoclonal plasma cells, typically affecting the axial skeleton and present as solitary bone lesions known as solitary bone plasmacytomas (SBP). Another type of plasmacytomas are extramedullary plasmacytomas (EP) that are localized plasma cell neoplasms affecting the soft tissues such as skin, brain lymph nodes etc. These tumors are account for 5-10% of all plasma cell disorders and among these tumors a rare entity is a multiple solitary plasmacytoma (MSP). MSPs are rare and account for only 5% of all SBPs. MSP presents with multiple SBPs with or without EPs with no bone marrow involvement as multiple myeloma. Literature is limited on MSP as it is a rare diagnosis. Here, we present a case of a 64-year-old male who presented with shoulder pain after a fall, found to have an SBP of the right shoulder, SBP of left femur and a left hypopharyngeal EP. The tumors were excised and he was treated with 6 cycles of bortezomib and dexamethasone. After chemotherapy and radiation patient showed good response and remained in remission on follow up.
{"title":"Multiple Solitary Plasmacytoma: A Rare Presentation","authors":"A. Kuchkuntla, N. Nandu","doi":"10.47363/jonrr/2021(2)124","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)124","url":null,"abstract":"Plasmacytomas are localized tumors of monoclonal plasma cells, typically affecting the axial skeleton and present as solitary bone lesions known as solitary bone plasmacytomas (SBP). Another type of plasmacytomas are extramedullary plasmacytomas (EP) that are localized plasma cell neoplasms affecting the soft tissues such as skin, brain lymph nodes etc. These tumors are account for 5-10% of all plasma cell disorders and among these tumors a rare entity is a multiple solitary plasmacytoma (MSP). MSPs are rare and account for only 5% of all SBPs. MSP presents with multiple SBPs with or without EPs with no bone marrow involvement as multiple myeloma. Literature is limited on MSP as it is a rare diagnosis. Here, we present a case of a 64-year-old male who presented with shoulder pain after a fall, found to have an SBP of the right shoulder, SBP of left femur and a left hypopharyngeal EP. The tumors were excised and he was treated with 6 cycles of bortezomib and dexamethasone. After chemotherapy and radiation patient showed good response and remained in remission on follow up.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134491269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)115
P. Lissoni, F. Rovelli
Today, it is known that inflammation represents the common mechanism of human systemic diseases, including cancer and autoimmunity. Obviously, the endothelial system is involved in all inflammatory processes. Then, the control of the endothelial functions could constitute a new medical strategy to treat several pathological conditions, including ischemic and thrombotic events. Moreover, in addition to the action of angiogenic and anti-angiogenic factors, the endothelial system has been proven to be physiologically under a double control, represent by the cytokine network and the neuroendocrine system. Most cytokines have appeared to exert angiogenic and inflammatory effects, which are balanced by an anti-angiogenic and an anti-inflammatory action exerted by the pineal hormone melatonin (MLT), cannabinoid agents, and the product of ACE2, the angiotensin 1-7 (Ang 1-7). Then, a neuroendocrine approach with MLT, cannabinoids and Ang 1-7 could constitute a new way in the treatment of endothelial alterations and angiogenesis.
{"title":"A Review on the Neuroendocrine Regulation of the Endothelial Cells","authors":"P. Lissoni, F. Rovelli","doi":"10.47363/jonrr/2021(2)115","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)115","url":null,"abstract":"Today, it is known that inflammation represents the common mechanism of human systemic diseases, including cancer and autoimmunity. Obviously, the endothelial system is involved in all inflammatory processes. Then, the control of the endothelial functions could constitute a new medical strategy to treat several pathological conditions, including ischemic and thrombotic events. Moreover, in addition to the action of angiogenic and anti-angiogenic factors, the endothelial system has been proven to be physiologically under a double control, represent by the cytokine network and the neuroendocrine system. Most cytokines have appeared to exert angiogenic and inflammatory effects, which are balanced by an anti-angiogenic and an anti-inflammatory action exerted by the pineal hormone melatonin (MLT), cannabinoid agents, and the product of ACE2, the angiotensin 1-7 (Ang 1-7). Then, a neuroendocrine approach with MLT, cannabinoids and Ang 1-7 could constitute a new way in the treatment of endothelial alterations and angiogenesis.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116421855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)118
Ahed J. Alkhatib, Shadi M. Alkhatib
Breast cancer is the most prevalent cancer affecting women. Identifying breast cancer risk factors are crucially to be established. The main objectives of the present study were to identify the predictors of breast cancer risk factors and their relative importance using neural network analysis. The present study depended on neural network analysis of data posted on [1]. The dataset is about predictors of breast cancer. There were 9 covariates included and one dependent variable, output (no disease (1), or disease (2)). The dataset was composed of 116 cases. The category of no disease comprised 79 (68.1%) cases, whereas the disease category included 37 cases (31.9%). Architecture model was built with some characteristics such as training part: gross entropy error was 23.7884, the percent of incorrect predictions was 10.1%. Stopping rule used was 1 consecutive step(s) with no decrease in error. For testing part, gross entropy error was 14,327, the percent of incorrect predictions was 13.5%. The relative importance of breast cancer was in the following order: glucose, resistin, BMI, age, leptin, adiponectin, MCP-1, insulin, and HOMA. Taken together, neural network analysis is an efficient tool to predict breast cancer risk factors.
{"title":"Prediction of Breast Cancer Risk Factors Using Neural Network Analytics: an Empirical Study","authors":"Ahed J. Alkhatib, Shadi M. Alkhatib","doi":"10.47363/jonrr/2021(2)118","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)118","url":null,"abstract":"Breast cancer is the most prevalent cancer affecting women. Identifying breast cancer risk factors are crucially to be established. The main objectives of the present study were to identify the predictors of breast cancer risk factors and their relative importance using neural network analysis. The present study depended on neural network analysis of data posted on [1]. The dataset is about predictors of breast cancer. There were 9 covariates included and one dependent variable, output (no disease (1), or disease (2)). The dataset was composed of 116 cases. The category of no disease comprised 79 (68.1%) cases, whereas the disease category included 37 cases (31.9%). Architecture model was built with some characteristics such as training part: gross entropy error was 23.7884, the percent of incorrect predictions was 10.1%. Stopping rule used was 1 consecutive step(s) with no decrease in error. For testing part, gross entropy error was 14,327, the percent of incorrect predictions was 13.5%. The relative importance of breast cancer was in the following order: glucose, resistin, BMI, age, leptin, adiponectin, MCP-1, insulin, and HOMA. Taken together, neural network analysis is an efficient tool to predict breast cancer risk factors.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127769007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)125
Jyoti P. Patel, Sindhu Shibu Nair
Background: To better primary health care and better-trained nurses, knowing the causes of cancer provides a basis for understanding the potential for prevention or early detection of the disease. Our study aimed to assess knowledge and awareness about breast, cervical and oral cancer screening amongst oncology nurses at a tertiary cancer centre. Methodology: An anonymised questionnaire based study was conducted amongst nurses at a tertiary cancer centre. We used NCG e-leaning questionnaire to assess knowledge (which includes breast, oral and cervical knowledge and awareness related questionnaire). Results: A total of 313 participants fulfilled the inclusion criteria and were enrolled in this study. Age range of participants was from 21 to 54 years (mean = 29.8; SD = 8.14). Knowledge and awareness about breast cancer were significantly associated gender (p=0.014) and marital status (p=0.00). Although, Knowledge and awareness about cervical cancer were significantly associated with gender (p=0.002) and years of experience (p=0.03). The age (p=0.001), marital status (p=0.002) and years of experience (p=<0.001) was statistically significantly associated with knowledge and awareness about oral cancer. Conclusion: Our data suggest that levels of knowledge and understanding of cervical cancer as well as its preventable nature should be improved. Continuing nurse education may contribute to strengthen cervical cancer screening programs. Nursing staff, if properly aware of this disease, can educate the masses and hence increase health-seeking behaviour in women.
{"title":"To Assess the Knowledge and Awareness about Breast, Cervical and Oral Cancer Screening Among Oncology Nurses in Tertiary Cancer Centre","authors":"Jyoti P. Patel, Sindhu Shibu Nair","doi":"10.47363/jonrr/2021(2)125","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)125","url":null,"abstract":"Background: To better primary health care and better-trained nurses, knowing the causes of cancer provides a basis for understanding the potential for prevention or early detection of the disease. Our study aimed to assess knowledge and awareness about breast, cervical and oral cancer screening amongst oncology nurses at a tertiary cancer centre. Methodology: An anonymised questionnaire based study was conducted amongst nurses at a tertiary cancer centre. We used NCG e-leaning questionnaire to assess knowledge (which includes breast, oral and cervical knowledge and awareness related questionnaire). Results: A total of 313 participants fulfilled the inclusion criteria and were enrolled in this study. Age range of participants was from 21 to 54 years (mean = 29.8; SD = 8.14). Knowledge and awareness about breast cancer were significantly associated gender (p=0.014) and marital status (p=0.00). Although, Knowledge and awareness about cervical cancer were significantly associated with gender (p=0.002) and years of experience (p=0.03). The age (p=0.001), marital status (p=0.002) and years of experience (p=<0.001) was statistically significantly associated with knowledge and awareness about oral cancer. Conclusion: Our data suggest that levels of knowledge and understanding of cervical cancer as well as its preventable nature should be improved. Continuing nurse education may contribute to strengthen cervical cancer screening programs. Nursing staff, if properly aware of this disease, can educate the masses and hence increase health-seeking behaviour in women.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123941985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)121
A. Kuchkuntla, Aarathi Reddy
With the advent of advanced imaging techniques such as positron emission topography/computed topography, use of radiotherapy in the management of various cancers has become more effective and is shown to have better outcomes. PET/CT scanning is useful for evaluating tumour biological heterogeneity of malignant lesions providing comprehensive information regards the tumour’s metabolism, hypoxia, and proliferation. Integration of PET/CT imaging in radiotherapy helps in assessing tumour volume to achieve effective tumour control by adjusting radiation dose. Literature is extensive on PET/CT based radiation planning and here we aim to provide a brief review of PET/CT use in different malignancies.
{"title":"Pet-Ct Based Radiotherapy Planning","authors":"A. Kuchkuntla, Aarathi Reddy","doi":"10.47363/jonrr/2021(2)121","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)121","url":null,"abstract":"With the advent of advanced imaging techniques such as positron emission topography/computed topography, use of radiotherapy in the management of various cancers has become more effective and is shown to have better outcomes. PET/CT scanning is useful for evaluating tumour biological heterogeneity of malignant lesions providing comprehensive information regards the tumour’s metabolism, hypoxia, and proliferation. Integration of PET/CT imaging in radiotherapy helps in assessing tumour volume to achieve effective tumour control by adjusting radiation dose. Literature is extensive on PET/CT based radiation planning and here we aim to provide a brief review of PET/CT use in different malignancies.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128203835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.47363/jonrr/2021(2)117
B. Petrikovsky
{"title":"Citiscreen Project for Cancer Screening: Colorectal, Prostate, Bladder, Testicular, Thyroid and Skin Cancers","authors":"B. Petrikovsky","doi":"10.47363/jonrr/2021(2)117","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)117","url":null,"abstract":"","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128231453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.47363/JONRR/2020(1)114
H. Al-Shamsi, Mona A. Alfares, S. Alrawi
As the current evidence is accumulating in support of multiple COVID-19 vaccine in general population while the final regulatory approvals are still pending, multiple vaccine candidates have already received temporary authorization for emergency use. The mRNA vaccines are new to the clinical practice and global regulators must balance the lack of medium to longer-term data on these novel mRNA COVID-19 vaccines.The inactivated vaccines have been used in cancer patients in the past with excellent safety profile and they may be theoretically the safest vaccine for cancer patients. Currently there are no formal COVID-19 vaccine trial designed specifically for cancer patients. Some of the current major trials excluded cancer patients while others did not explicitly excluded malignancies. Early reports indicate that some cancer patients were able to enroll in some of the vaccine trials, yet no clear information if these patients were on active systemic therapies or surveillance. There is a need for a dedicated COVID-19 vaccine trials for cancer patients. The UK Independent report by the “ Joint Committee on Vaccination and Immunisation for the Priority groups for coronavirus (COVID-19) vaccination” recommended “bone marrow and stem cell transplant recipients and people with specific cancers” to receive priority vaccination, without further clarification which “specific cancers” were referred to. Until further data are available, recommendations for vaccination for COVID-19 for cancer patients cannot be routinely recommended. At the current time evaluation of cancer patients who wish to consider COVID-19 vaccination should be done in the context of clinical trials, if there is no access to clinical trials; This should be addressed “case by case” basis with clear discussion about potential benefits, risks and uncertainties surrounding COVID-19 vaccination for cancer patients at the current time.
{"title":"COVID-19 Vaccination for Cancer Patients, What Oncologists and Cancer Patients Need to Know?","authors":"H. Al-Shamsi, Mona A. Alfares, S. Alrawi","doi":"10.47363/JONRR/2020(1)114","DOIUrl":"https://doi.org/10.47363/JONRR/2020(1)114","url":null,"abstract":"As the current evidence is accumulating in support of multiple COVID-19 vaccine in general population while the final regulatory approvals are still pending, multiple vaccine candidates have already received temporary authorization for emergency use. The mRNA vaccines are new to the clinical practice and global regulators must balance the lack of medium to longer-term data on these novel mRNA COVID-19 vaccines.The inactivated vaccines have been used in cancer patients in the past with excellent safety profile and they may be theoretically the safest vaccine for cancer patients. Currently there are no formal COVID-19 vaccine trial designed specifically for cancer patients. Some of the current major trials excluded cancer patients while others did not explicitly excluded malignancies. Early reports indicate that some cancer patients were able to enroll in some of the vaccine trials, yet no clear information if these patients were on active systemic therapies or surveillance. There is a need for a dedicated COVID-19 vaccine trials for cancer patients. The UK Independent report by the “ Joint Committee on Vaccination and Immunisation for the Priority groups for coronavirus (COVID-19) vaccination” recommended “bone marrow and stem cell transplant recipients and people with specific cancers” to receive priority vaccination, without further clarification which “specific cancers” were referred to. Until further data are available, recommendations for vaccination for COVID-19 for cancer patients cannot be routinely recommended. At the current time evaluation of cancer patients who wish to consider COVID-19 vaccination should be done in the context of clinical trials, if there is no access to clinical trials; This should be addressed “case by case” basis with clear discussion about potential benefits, risks and uncertainties surrounding COVID-19 vaccination for cancer patients at the current time.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114262426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：